These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31351990)

  • 1. Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma.
    Faivre G; Butler MJ; Le I; Brenner A
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):665-669. PubMed ID: 31351990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
    Yu J; Du H; Ye X; Zhang L; Xiao H
    Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.
    Glass J; Won M; Schultz CJ; Brat D; Bartlett NL; Suh JH; Werner-Wasik M; Fisher BJ; Liepman MK; Augspurger M; Bokstein F; Bovi JA; Solhjem MC; Mehta MP
    J Clin Oncol; 2016 May; 34(14):1620-5. PubMed ID: 27022122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
    Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K
    J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical Efficacy of High Dose Methotrexate, Temozolomide and Rituximab in the Treatment of Patients with Primary Central Nervous System Lymphoma].
    Pang DW; Chen FL; Guo HG; Jiang XM; Wei XJ; Liu SC; Huang L; Liang ZL; Li WY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1175-1180. PubMed ID: 34362499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.
    Chen C; Sun P; Cui J; Yan S; Chen H; Xia Y; Bi X; Liu P; Wang Y; Yang H; Nie M; Zhang XW; Jiang W; Li ZM
    Cancer Med; 2019 Apr; 8(4):1359-1367. PubMed ID: 30821418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly.
    Fritsch K; Kasenda B; Hader C; Nikkhah G; Prinz M; Haug V; Haug S; Ihorst G; Finke J; Illerhaus G
    Ann Oncol; 2011 Sep; 22(9):2080-2085. PubMed ID: 21303800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
    Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K
    Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma.
    Wang Y; Liu B; Xu D; Zhao H; Zhu Y; Xu J; Tao R
    Neurol India; 2013; 61(3):260-4. PubMed ID: 23860145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.
    Morris PG; Correa DD; Yahalom J; Raizer JJ; Schiff D; Grant B; Grimm S; Lai RK; Reiner AS; Panageas K; Karimi S; Curry R; Shah G; Abrey LE; DeAngelis LM; Omuro A
    J Clin Oncol; 2013 Nov; 31(31):3971-9. PubMed ID: 24101038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
    Omuro A; Correa DD; DeAngelis LM; Moskowitz CH; Matasar MJ; Kaley TJ; Gavrilovic IT; Nolan C; Pentsova E; Grommes CC; Panageas KS; Baser RE; Faivre G; Abrey LE; Sauter CS
    Blood; 2015 Feb; 125(9):1403-10. PubMed ID: 25568347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment for primary CNS lymphoma: the next step.
    Abrey LE; Yahalom J; DeAngelis LM
    J Clin Oncol; 2000 Sep; 18(17):3144-50. PubMed ID: 10963643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
    Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K
    Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy.
    Sasaki N; Kobayashi K; Saito K; Shimizu S; Suzuki K; Lee J; Yamagishi Y; Shibahara J; Takayama N; Shiokawa Y; Nagane M
    Jpn J Clin Oncol; 2020 Sep; 50(9):999-1008. PubMed ID: 32469065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.
    Illerhaus G; Marks R; Müller F; Ihorst G; Feuerhake F; Deckert M; Ostertag C; Finke J
    Ann Oncol; 2009 Feb; 20(2):319-25. PubMed ID: 18953065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy.
    Chiesa S; Hohaus S; Falcinelli L; D'Alò F; Martelli MF; Manfrida S; Beghella Bartoli F; Colosimo C; Valentini V; Aristei C; Balducci M
    Ann Hematol; 2020 Oct; 99(10):2367-2375. PubMed ID: 32816079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.
    David KA; Sundaram S; Kim SH; Vaca R; Lin Y; Singer S; Malecek MK; Carter J; Zayac A; Kim MS; Reddy N; Ney D; Habib A; Strouse C; Graber J; Bachanova V; Salman S; Vendiola JA; Hossain N; Tsang M; Major A; Bond DA; Agrawal P; Mier-Hicks A; Torka P; Rajakumar P; Venugopal P; Berg S; Glantz M; Goldlust SA; Folstad M; Kumar P; Ollila TA; Cai J; Spurgeon S; Sieg A; Cleveland J; Chang J; Epperla N; Karmali R; Naik S; Martin P; Smith SM; Rubenstein J; Kahl B; Evens AM
    Am J Hematol; 2023 Jun; 98(6):900-912. PubMed ID: 36965007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.
    Alcantara M; Chevrier M; Jardin F; Schmitt A; Houillier C; Oberic L; Chinot O; Morschhauser F; Peyrade F; Houot R; Hoang-Xuan K; Ghesquieres H; Soussain C
    J Hematol Oncol; 2024 Sep; 17(1):86. PubMed ID: 39300447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.